Mr. Stapley has deep experience in the genomic diagnostics industry, including significant expertise building and leading complex global operations.

Her career spans over 40 years in regulated diagnostics and life science markets. She co-founded Veracyte in 2008 and served as Chief Executive Officer and Chairman of the Board until June 1, 2021, when she assumed the role of Executive Chairwoman.

Giulia C. Kennedy, Ph.D., is Veracyte’s Global Chief Scientific and Medical Officer, overseeing a global team of research and development, medical affairs, data science and clinical affairs professionals to fuel the company’s novel tests and pipeline.

Rebecca Chambers has extensive healthcare leadership experience, previously serving as Chief Financial Officer for Outset Medical, a publicly traded medical technology company focused on reducing dialysis cost and complexity.

Tina S. Nova, Ph.D., serves as President of Veracyte’s CLIA U.S. Business. In this role, she leads all aspects – market development, product marketing, reimbursement, sales and lab operations – of the company’s broad menu of diagnostic tests that are performed in its laboratories, serving physicians and their patients in the United States.

Stephane Debono is a seasoned executive and entrepreneur who brings more than 25 years of life sciences and healthcare experience to Veracyte.

Rob Brainin is a seasoned professional with over 20 years of executive life sciences and healthcare experience, and a proven track record of using emerging technologies and data science to improve healthcare.

Bill Zondler’s career spans more than 25 years in information technology, including over 20 years in clinical laboratories and the pharmaceutical, medical device, life sciences and biotechnology industries.

Vincent Fert has extensive diagnostic leadership experience, most recently serving as the Founder, Chairman and Chief Executive Officer of HalioDx, an immuno-oncology diagnostics company recently acquired by Veracyte.

Morten Frost leads sales, marketing, and market access for the company’s diagnostics tests, serving physicians and their patients in global markets, as well as Veracyte’s companion diagnostic development services for biopharmaceutical companies.

Corinne Danan serves as Veracyte’s General Manager, Biopharma, leading the company’s offerings to biopharmaceutical companies. Ms. Danan brings more than 30 years of executive experience in the pharmaceutical, life sciences and healthcare industries, as well as strong leadership in Commercial Operations, to her role at Veracyte.

Fabienne Hermitte, Ph.D., brings deep expertise in clinical diagnostics to her role at Veracyte. She cofounded HalioDx, an immuno-oncology diagnostics company, in 2015. At HalioDx, she led the Regulatory, Quality, Medical Affairs, Clinical Development and Diagnostic Marketing teams prior to the company’s acquisition by Veracyte in August 2021.

In this role, she works in tandem with the Chief Executive Officer and executive team to communicate the company’s strategic vision and value proposition to investors and other audiences and ensures that the market-leading company’s brand is articulated in product and other communications.

Kate Godfrey joined Veracyte as Chief Compliance and Privacy Officer in November of 2021 and is responsible for the company’s enterprise-wide compliance programs, which manage risks associated with all core business activities, as well as its global privacy program.